Design of a phase 3, prospective, multicenter, open-label study of safety and hemostatic efficacy of rurioctocog alfa pegol in previously untreated patients <6 years of age with severe hemophilia A

被引：0
|
作者：
Mullins, E. [1 ,2 ]
Kefurt, C. [3 ]
Engl, W. [3 ]
Tangada, S. [4 ]
机构：
[1] Univ Cincinnati, Coll Med, Cincinnati, OH USA
[2] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA
[3] Shire, Vienna, Austria
[4] Shire, Lexington, MA USA
来源：
HAEMOPHILIA | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P095
引用
收藏
页码：83 / 83
页数：1
相关论文
共 50 条
  • [21] Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study)
    Radulescu, V.
    Klamroth, R.
    Windyga, J.
    Collins, P.
    Stasyshyn, O.
    Ibrahim, H. Mohd
    Engl, W.
    Tangada, S.
    Savage, W.
    Ewenstein, B.
    HAEMOPHILIA, 2019, 25 : 57 - 58
  • [22] Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study)
    Klamroth, R.
    Windyga, J.
    Radulescu, V.
    Collins, P.
    Stasyshyn, O.
    Ibrahim, H. M.
    Engl, W.
    Tangada, S.
    Savage, W.
    Ewenstein, B.
    HAEMOPHILIA, 2019, 25 : 162 - 162
  • [23] A Randomized, Multicenter, Open-Label Phase 3 Study to Evaluate the Safety and Efficacy of Infliximab in Pediatric Patients With Moderate to Severe Ulcerative Colitis
    Hyarns, Jeffrey S.
    Damaraju, Lakshmi
    Blank, Marion
    Johanns, Jewel
    Guzzo, Cynthia
    Winter, Harland S.
    Kugathasan, Sabra
    Cohen, Stanley A.
    Markowitz, James
    Veereman, Gigi
    Crandall, Wallace
    Baldassano, Robert
    Griffiths, Anne M.
    GASTROENTEROLOGY, 2011, 140 (05) : S124 - S125
  • [24] A Phase II, Multicenter, Open-Label Study of Obatoclax Mesylate in Patients With Previously Untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia
    Arellano, Martha L.
    Borthakur, Gautam
    Berger, Mark
    Luer, Jill
    Raza, Azra
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (06): : 534 - 539
  • [25] Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study
    Uchida, Haruhito A.
    Nakajima, Hirofumi
    Hashimoto, Masami
    Nakamura, Akihiko
    Nunoue, Tomokazu
    Murakami, Kazuharu
    Hosoya, Takeshi
    Komoto, Kiichi
    Taguchi, Takashi
    Akasaka, Takaaki
    Shiosakai, Kazuhito
    Sugimoto, Kotaro
    Wada, Jun
    ADVANCES IN THERAPY, 2022, 39 (11) : 5158 - 5175
  • [26] Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study
    Haruhito A. Uchida
    Hirofumi Nakajima
    Masami Hashimoto
    Akihiko Nakamura
    Tomokazu Nunoue
    Kazuharu Murakami
    Takeshi Hosoya
    Kiichi Komoto
    Takashi Taguchi
    Takaaki Akasaka
    Kazuhito Shiosakai
    Kotaro Sugimoto
    Jun Wada
    Advances in Therapy, 2022, 39 : 5158 - 5175
  • [27] Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis
    Michael J. Cork
    Diamant Thaçi
    Lawrence F. Eichenfield
    Peter D. Arkwright
    Zhen Chen
    Ryan B. Thomas
    Matthew P. Kosloski
    Ariane Dubost-Brama
    Randy Prescilla
    Ashish Bansal
    Noah A. Levit
    Dermatology and Therapy, 2023, 13 : 2697 - 2719
  • [28] Efficacy and safety of prophylaxis with recombinant von Willebrand factor (VWF) in severe von Willebrand disease (VWD): Design of a prospective, phase 3, open-label, international multicenter study
    Leebeek, F. W.
    Kavakli, K.
    Genre-Volot, F.
    Peyvandi, F.
    Miesbach, W.
    Shapiro, A.
    Timofeeva, M.
    Martell, L.
    Abrol, S.
    Ozen, G.
    Mellgard, B.
    HAEMOPHILIA, 2019, 25 : 90 - 90
  • [29] A PHASE IV, OPEN-LABEL, MULTICENTER PILOT STUDY WITH DROTRECOGIN ALFA (ACTIVATED) IN THE TREATMENT OF BURN PATIENTS WITH SEVERE SEPSIS
    Friedman, Bruce
    Shaver, Joseph
    Mullins, Robert
    Hassan, Zaheed
    Brandigi, Claus
    CRITICAL CARE MEDICINE, 2010, 38 (12) : U242 - U242
  • [30] Efficacy and safety of aliskiren in Japanese patients with severe hypertension: An 8 week, multicenter, uncontrolled, open-label study
    Kushiro, T.
    Le Breton, S.
    Takabayashi, N.
    JOURNAL OF HYPERTENSION, 2008, 26 : S468 - S469
12345